Clinical Trials Directory

The purpose of this study is to understand the safety of IDE196 when given before and after treatment.

We are doing this study to find out if an experimental drug called IDE196 (the study drug) is a safe and effective treatment for uveal melanoma (melanoma in the eye) that has spread to another part of the body or other types of cancer with a tumor mutation in genes called GNAQ, GNA11, or PRKC.

We are doing this study to compare the outcomes of people who get their after-transplant care in the hospital versus in their home. This study is important to learn if getting after-transplant care in a patient's home can lead to better outcomes.

We are doing this study to find out if an experimental drug called IMM-1-104 (the study drug) is a safe and effective option for patients with melanoma, pancreatic cancer, or lung cancer. We also want to find out what dose of the study drug works best.

We are doing this study to learn more about prostate cancer and whether certain treatments are related with different outcomes and patient experiences.

We are doing this study to find out if the drugs talquetamab and teclistamab are a safe and effective option for people with multiple myeloma that has come back after treatment (relapsed) or is not improving with treatment (refractory).

We are doing this study to find out if the study drug JCAR017 is safe and to find out what dose is recommended for patients with relapsed/refractory CLL or SLL.

We are doing this study to find out if an experimental drug called KTX-1001 (the study drug) is a safe and effective treatment for multiple myeloma. We want to identify the most appropriate dose and dosing schedule of the study drug for patients with multiple myeloma.